Brief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
29/09/2026 07:38
BRIEF-AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027 Sept 29 (Reuters) - AB Science SA ABS.PA:
AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION
AB SCIENCE - EXPECTS TO RESUME AB8939 PHASE 1 IN Q1 2027 AND MASITINIB PHASE 3 IN Q4 2027
AB SCIENCE - REVISES OPERATING PLAN AFTER GCP INSPECTION BY FRANCE, DENMARK, GREECE AUTHORITIES
Source text: ID:nGNXc3CM4t
Further company coverage: ABS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041